Canada's Federal Court of Appeal, reversing a lower court ruling, has prohibited the Canadian subsidiary of Ranbaxy Laboratories Ltd. from marketing a generic version of Pfizer Canada Inc.'s cholesterol-reducing drug Lipitor until the expiration of Pfizer's patents.rnJustice Marc Nadon, writing the unanimous ruling for the three-member panel, said that the Federal Court of Canada had erred in dismissing Pfizer's application to strike down a Notice of Allegation filed by Ranbaxy that argued Pfizer's patent 2,021,546 for Lipitor was invalid on the basis of obviousness, double patenting, insufficiency, and anticipation.
展开▼
